Peridontal infections due to susceptible strains of both aerobic and anaerobic bacteria. Staphylococcus aureus, β-lactamase-producing strain of this organism has been demonstrated in vivo.

Amoxicillin is a broad-spectrum antibiotic that is effective against many gram-positive and -negative bacteria, aerobic and anaerobic microorganisms. It does not resist destruction by β-lactamases; therefore, it is not effective against β-lactamase-producing bacteria. Chimerically, it is D(-)-al-amino-p-hydroxybenzyl penicillin trihydrate. Amoxicillin is stable in the presence of gastric acid and is not significantly influenced by gastric or intestinal contents. The 2 components are rapidly absorbed resulting in amoxicillin and clavulanic acid concentrations in serum, urine, and tissues similar to those produced when each is administered alone.

Amoxicillin and clavulanic acid are rapidly and selectively absorbed in digestive tract leading to both plasma and tissue distribution. They are distributed in all body fluids and tissues with the exception of bone and spinal fluid, which amoxicillin penetrates adequately when meninges are inflamed. Most of the amoxicillin is excreted unchanged in the urine. Clavulanic acid is excreted into the renal fluid and urine within the first 6 hours.

Clavulanic acid includes β-lactamase-producing strains of amoxicillin to include penicillins resistant to amoxicillin and other β-lactam antibiotics.

Amoxicillin/clavulanate has been shown to have a wide range of activity which includes β-lactamase-producing strains of both gram-positive and -negative aerobes, facultative anaerobes, and obligate anaerobes. Many strains of the following organisms, including β-lactamase-producing strains, isolated from veterinary sources, were found to be susceptible to amoxicillin/clavulanate in vitro but the clinical significance of this activity has not been demonstrated for some of these organisms in animals. Aerobic bacteria, including Staphylococcus aureus*, β-lactamase-producing Staphylococcus aureus*, Staphylococcus epidermidis, Staphylococcus intermedius, Streptococcus faecalis, Streptococcus pneumoniae*, Corynebacterium pyogenes, Corynebacterium species, Erysipelothrix rhusiopathiae, Bordetella bronchiseptica, Escherichia coli*, Proteus mirabilis, Proteus species, Enterobacter species, Klebsiella pneumoniae, Salmonella dublin, Salmonella typhimurium, Pasteurella multocida*, Pasteurella haemolytica, Pasteurella species*. The susceptibility of these organisms has also been demonstrated in vivo studies.

Studies have demonstrated that both aerobic and anaerobic flora is isolated from gingival cultures of dogs with clinical evidence of periodontal disease. Both gram-positive and gram-negative aerobic and anaerobic subgingival isolates indicate sensitivity to amoxicillin/clavulanate during antimicrobial susceptibility testing.


INDICATIONS AND USAGE: Clavamox Drops are indicated in the treatment of:
- Dogs: Skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: β-lactamase-producing Staphylococcus aureus, non-β-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli.
- Cats: Skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: β-lactamase-producing Staphylococcus aureus, non-β-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli.

Peridontal infections due to susceptible strains of both aerobic and anaerobic bacteria. Clavamox has been shown to be clinically effective for treating cases of canine periodontal disease.

For use in dogs and cats

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Clavamox (amoxicillin trihydrate/clavulanate potassium) is an orally administered formulation comprised of the broad-spectrum antibiotic Amoxi® (amoxicillin trihydrate) and the β-lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid).

Amoxicillin trihydrate is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and -negative aerobic and anaerobic microorganisms. It does not resist destruction by β-lactamases; therefore, it is not effective against β-lactamase-producing bacteria. Chimerically, it is D(-)-al-amino-p-hydroxybenzyl penicillin trihydrate.

Clavulanic acid, an inhibitor of β-lactamase enzymes, is produced by the fermentation of Streptomycetes clavuligerus. Clavulanic acid by itself has only weak antibacterial activity. Chimerically, clavulanate potassium is potassium z-(3R,5R)-2-β-hydroxyethylidene clavam-3-carboxylate.

CLINICAL PHARMACOLOGY: Clavamox is stable in the presence of gastric acid and is not significantly influenced by gastric or intestinal contents. The 2 components are rapidly absorbed resulting in amoxicillin and clavulanic acid concentrations in serum, urine, and tissues similar to those produced when each is administered alone.

Amoxicillin and clavulanic acid are rapidly and selectively absorbed in digestive tract leading to both plasma and tissue distribution. They are distributed in all body fluids and tissues with the exception of bone and spinal fluid, which amoxicillin penetrates adequately when meninges are inflamed. Most of the amoxicillin is excreted unchanged in the urine. Clavulanic acid is excreted into the renal fluid and urine within the first 6 hours.

Clavulanic acid includes β-lactamase-producing strains of amoxicillin to include β-lactamase-producing as well as non-β-lactamase-producing aerobic and anaerobic organisms.

Microbiology: Amoxicillin is bactericidal in action and acts through the inhibition of biosynthesis of cell wall mucoprotein of susceptible organisms. The action of clavulanic acid extends the antimicrobial spectrum of amoxicillin to include organisms resistant to amoxicillin and other β-lactam antibiotics.

Amoxicillin/clavulanate has been shown to have a wide range of activity which includes β-lactamase-producing strains of both gram-positive and -negative aerobes, facultative anaerobes, and obligate anaerobes. Many strains of the following organisms, including β-lactamase-producing strains, isolated from veterinary sources, were found to be susceptible to amoxicillin/clavulanate in vitro but the clinical significance of this activity has not been demonstrated for some of these organisms in animals. Aerobic bacteria, including Staphylococcus aureus*, β-lactamase-producing Staphylococcus aureus*, Staphylococcus epidermidis, Staphylococcus intermedius, Streptococcus faecalis, Streptococcus pneumoniae*, Corynebacterium pyogenes, Corynebacterium species, Erysipelothrix rhusiopathiae, Bordetella bronchiseptica, Escherichia coli*, Proteus mirabilis, Proteus species, Enterobacter species, Klebsiella pneumoniae, Salmonella dublin, Salmonella typhimurium, Pasturella multocida*, Pasteurella haemolytica, Pasteurella species*.

* The susceptibility of these organisms has also been demonstrated in in vivo studies.

Studies have demonstrated that both aerobic and anaerobic flora is isolated from gingival cultures of dogs with clinical evidence of periodontal disease. Both gram-positive and gram-negative aerobic and anaerobic subgingival isolates indicate sensitivity to amoxicillin/clavulanate during antimicrobial susceptibility testing.


INDICATIONS AND USAGE: Clavamox Drops are indicated in the treatment of:
- Dogs: Skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: β-lactamase-producing Staphylococcus aureus, non-β-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli.

Peridontal infections due to susceptible strains of both aerobic and anaerobic bacteria. Clavamox has been shown to be clinically effective for treating cases of canine periodontal disease.

CONTRAINDICATIONS: The use of this drug is contraindicated in animals with a history of an allergic reaction to any of the penicillins or cephalosporins.

WARNINGS: Safety of use in pregnant or breeding animals has not been determined. For use in dogs and cats only.

ADVERSE REACTIONS: Clavamox contains a semisynthetic penicillin (amoxicillin) and has the potential for producing allergic reactions.

If an allergic reaction occurs, administer epinephrine and/or steroids.

DOSEAGE AND ADMINISTRATION:
- Dogs: The recommended dosage is 6.25 mg/lb (1 mL/10 lb) of body weight twice a day. Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5–7 days or for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.

- Cats: The recommended dosage is 62.5 mg (1 mL) twice a day. Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5–7 days or 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated.

Urinary tract infections may require treatment for 10–14 days or longer. The maximum duration of treatment should not exceed 30 days.

Reconstitution instructions - Oral Suspension: Add 14 mL of water to the 15-mL bottle and shake vigorously. Each mL of suspension will contain 50 mg of amoxicillin activity as the trihydrate and 12.5 mg of clavulanic acid activity as the potassium salt.

Note: Any unused portion of the reconstituted suspension must be discarded after 10 days. Refrigeration of the reconstituted suspension is required.

HOW SUPPLIED: Clavamox Drops are supplied in 15-mL bottles containing 50 mg of amoxicillin/12.5 mg of clavulanic acid per mL.

NADA #55-101, Approved by FDA

Clavamox is a trademark owned by and used under license from GlaxoSmithKline.

Augmentin is a trademark owned by GlaxoSmithKline.

Manufactured by:
Norbrook Laboratories Ltd.
Newry, N. Ireland, UK

Distributed by:
Zoetis Inc.
Kalamazoo, MI 49007

018544101A&P
Revised: July 2014